Literature DB >> 18713907

Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication.

Ulrike M Stamer1, Frank Stüber, Thomas Muders, Frank Musshoff.   

Abstract

We observed opioid-related respiratory depression in a patient receiving tramadol via patient-controlled analgesia. Predisposing factors were the patient's genetic background and renal impairment. Complete recovery occurred after naloxone administration, thus confirming opioid intoxication. Analysis of the patient's genotype revealed a CYP2D6 gene duplication resulting in ultra-rapid metabolism of tramadol to its active metabolite (+)O-desmethyltramadol. Concomitant renal impairment resulting in decreased metabolite clearance enhanced opioid toxicity. This genetic CYP2D6 variant is particularly common in specific ethnic populations and should be a future diagnostic target whenever administration of tramadol or codeine is anticipated, as both drugs are subject to a comparable CYP2D6-dependent metabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18713907     DOI: 10.1213/ane.0b013e31817b796e

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  35 in total

Review 1.  Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU.

Authors:  Isabel Spriet; Wouter Meersseman; Jan de Hoon; Sandrina von Winckelmann; Alexander Wilmer; Ludo Willems
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

Review 2.  Value of Supportive Care Pharmacogenomics in Oncology Practice.

Authors:  Jai N Patel; Lauren A Wiebe; Henry M Dunnenberger; Howard L McLeod
Journal:  Oncologist       Date:  2018-04-05

Review 3.  Mechanism based medicine in infancy: complex interplay between developmental pharmacology and pharmacogenetics.

Authors:  Karel Allegaert
Journal:  Int J Clin Pharm       Date:  2011-06

Review 4.  Genetics of perioperative pain management.

Authors:  Senthil Packiasabapathy; Nicole Horn; Senthilkumar Sadhasivam
Journal:  Curr Opin Anaesthesiol       Date:  2018-12       Impact factor: 2.706

5.  [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies].

Authors:  M Merker; G Dinges; T Koch; P Kranke; A M Morin
Journal:  Schmerz       Date:  2012-02       Impact factor: 1.107

6.  Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study.

Authors:  Karel Allegaert; Nick Holford; Brian J Anderson; Sam Holford; Frank Stuber; Alain Rochette; Iñaki F Trocóniz; Horst Beier; Jan N de Hoon; Rasmus S Pedersen; Ulrike Stamer
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

7.  PharmGKB summary: tramadol pathway.

Authors:  Li Gong; Ulrike M Stamer; Mladen V Tzvetkov; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-07       Impact factor: 2.089

8.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.

Authors:  K R Crews; A Gaedigk; H M Dunnenberger; T E Klein; D D Shen; J T Callaghan; E D Kharasch; T C Skaar
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

9.  Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.

Authors:  Hironari Tanaka; Takafumi Naito; Hikaru Sato; Takanori Hiraide; Yasuhide Yamada; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2018-07-26       Impact factor: 2.953

Review 10.  The Pharmacogenetics of Tramadol.

Authors:  Dorte Lassen; Per Damkier; Kim Brøsen
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.